A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
← catalyst calendarNCT07553442 · readout in 590 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →. With Hoffmann-La Roche.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
93estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-27 | actual | When the study began enrolling |
| Primary completion | 2028-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypertension
Interventions
- Drug: ALN-AGT01 RVR
- Drug: Placebo
- Drug: Zilebesiran
Primary outcomes
what the primary-completion date above is the date OFPart A: Percentage recovery from baseline in serum AGT
measured Up to Day 4
Part B: Percentage recovery from baseline in mean seated office SBP
measured At Day 4 and Day 7
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed